NCT05504395View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Prader-Willi Syndrome
Interventions
DRUG

CSTI-500

Single 10 mg capsule

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
lead

ConSynance Therapeutics

INDUSTRY